EVOLUS, INC. Total Liabilities and Equity
EVOLUS, INC. (EOLS) had Total Liabilities and Equity of $248.02 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-05
- 2026-06-30: Liabilities and Equity $248.02M.
- 2026-03-31: Liabilities and Equity $220.65M.
- 2025-12-31: Liabilities and Equity $225.87M.
- 2025-09-30: Liabilities and Equity $219.00M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $248.02M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $220.65M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $225.87M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $219.00M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $228.80M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $213.36M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $232.57M 10-K · filed 2026-03-03 |
| 2024-09-30 | $229.61M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $233.77M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $226.18M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $189.00M 10-K · filed 2025-03-04 |
| 2023-09-30 | $167.97M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $168.98M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $160.24M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $177.98M 10-K · filed 2024-03-07 |
| 2022-09-30 | $192.72M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $210.92M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $220.66M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $257.48M 10-K · filed 2023-03-08 |
| 2021-09-30 | $215.22M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $239.86M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $157.20M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $209.07M 10-K · filed 2022-03-03 |
| 2020-09-30 | $215.78M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $194.54M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $214.15M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $240.44M 10-K · filed 2021-03-25 |
| 2019-09-30 | $182.67M 10-Q · filed 2019-11-04 |
| 2019-06-30 | $202.78M 10-Q · filed 2019-08-12 |
| 2019-03-31 | $220.93M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $171.84M 10-K · filed 2020-02-25 |
| 2018-09-30 | $183.38M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $121.93M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $127.39M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $152.23M 10-K · filed 2019-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |